VIPADENANT

/static/temp/default.svg

Search structure


Synonyms	BIIB-014 BIIB014 Biib014 CEB-4520 V-2006 V2006 VER-11135 VER-A-00-11 VER-A-00049 VER-A00-11 VER-A00049 VER-ADO-49 Vipadenant
Status
Molecule Category	UNKNOWN
UNII	LDR3USH1NJ
EPA CompTox	DTXSID90196103


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	HQSBCDPYXDGTCL-UHFFFAOYSA-N
Smiles	Cc1cc(Cn2nnc3c(-c4ccco4)nc(N)nc32)ccc1N
InChI	InChI=1S/C16H15N7O/c1-9-7-10(4-5-11(9)17)8-23-15-14(21-22-23)13(19-16(18)20-15)12-3-2-6-24-12/h2-7H,8,17H2,1H3,(H2,18,19,20)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C16H15N7O
Molecular Weight	321.34
AlogP	2.0
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	3.0
Polar Surface Area	121.67
Molecular species	NEUTRAL
Aromatic Rings	4.0
Heavy Atoms	24.0

Bioactivity

Mechanism of Action	Action	Reference
Adenosine A2a receptor antagonist	ANTAGONIST	PubMed PubMed


Protein: Adenosine A2a receptor Description: Adenosine receptor A2a Organism : Homo sapiens P29274 ENSG00000128271

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Nucleotide-like receptor (family A GPCR) Adenosine receptor	-	-	1	1-1	-

Assay Description	Organism	Bioactivity	Reference
Displacement of radioligand from human recombinant adenosine A2A receptor at 21 degC after 90 mins by cell-based microplate scintillation counting	Homo sapiens	1.3 nM
Displacement of radioligand from human recombinant adenosine A1 receptor at 21 degC after 90 mins by cell-based microplate scintillation counting	Homo sapiens	68.0 nM
Displacement of radioligand from human recombinant adenosine A2B receptor at 21 degC after 60 mins by cell-based microplate scintillation counting	Homo sapiens	63.0 nM
Antagonist activity at human adenosine A2A receptor expressed in CHO-K1 cells treated for 15 mins by calcium mobilization-based FLIPR assay	Homo sapiens	0.631 nM
Antagonist activity at human adenosine A2B receptor expressed in CHO-K1 cells by calcium mobilization-based FLIPR assay	Homo sapiens	31.62 nM
Antagonist activity at human adenosine A1 receptor expressed in CHO-K1 cells by calcium mobilization-based FLIPR assay	Homo sapiens	100.0 nM
Inhibition of human recombinant adenosine receptor A2b	Homo sapiens	63.0 nM
Inhibition of human recombinant adenosine receptor A2a	Homo sapiens	1.3 nM
Inhibition of human recombinant adenosine A1 receptor	Homo sapiens	68.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	36.83 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	2.854 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.09 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.09 %

Related Entries

Cross References

Resources	Reference
ChEMBL	CHEMBL447664
DrugBank	DB06625
FDA SRS	LDR3USH1NJ
Guide to Pharmacology	5612
PDB	9XT
PubChem	21874557
SureChEMBL	SCHEMBL2849027
ZINC	ZINC000040863182

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).